Immunosuppressive therapy for aplastic anemia--review.
- Author:
Chong-Yan XU
1
Author Information
1. Institute of Hematology, Hematologic Hospital, Union Medical University of China, Chinese Academy of Medical Science, Tainjing 300020, China. xcysd@sohu.com
- Publication Type:Journal Article
- MeSH:
Anemia, Aplastic;
drug therapy;
Antilymphocyte Serum;
therapeutic use;
Cyclosporine;
therapeutic use;
Drug Therapy, Combination;
Erythropoietin;
therapeutic use;
Granulocyte-Macrophage Colony-Stimulating Factor;
therapeutic use;
Humans;
Immunosuppressive Agents;
therapeutic use;
Recombinant Proteins
- From:
Journal of Experimental Hematology
2005;13(2):348-352
- CountryChina
- Language:Chinese
-
Abstract:
Immunosuppressive therapy (IST) is essential to treat aplastic anemia. The pharmacological mechanism, therapeutic effect of main drugs and their application method, reasonable dosage, synergistic action are briefly reviewed in this article. These reviewed drugs include ATG/ALG, CsA, ALG/ATG + CsA, IIST (ALG + CsA) + HGFs, McAb-T, HD-MP and HD-IVIG. The purpose of this review was to direct to clinical therapy for patients with aplastic anemia.
